Abstract

Inflammatory diseases and cancer metastases lack concrete pharmaceuticals for their effective treatment despite great strides in advancing our understanding of disease progression. One feature of these disease pathogeneses that remains to be fully explored, both biologically and pharmaceutically, is the passage of cancer and immune cells from the blood to the underlying tissue in the process of extravasation. Regardless of migratory cell type, all steps in extravasation involve molecular interactions that serve as a rich landscape of targets for pharmaceutical inhibition or promotion. Transendothelial migration (TEM), or the migration of the cell through the vascular endothelium, is a particularly promising area of interest as it constitutes the final and most involved step in the extravasation cascade. While in vivo models of cancer metastasis and inflammatory diseases have contributed to our current understanding of TEM, the knowledge surrounding this phenomenon would be significantly lacking without the use of in vitro platforms. In addition to the ease of use, low cost, and high controllability, in vitro platforms permit the use of human cell lines to represent certain features of disease pathology better, as seen in the clinic. These benefits over traditional pre-clinical models for efficacy and toxicity testing are especially important in the modern pursuit of novel drug candidates. Here, we review the cellular and molecular events involved in leukocyte and cancer cell extravasation, with a keen focus on TEM, as discovered by seminal and progressive in vitro platforms. In vitro studies of TEM, specifically, showcase the great experimental progress at the lab bench and highlight the historical success of in vitro platforms for biological discovery. This success shows the potential for applying these platforms for pharmaceutical compound screening. In addition to immune and cancer cell TEM, we discuss the promise of hepatocyte transplantation, a process in which systemically delivered hepatocytes must transmigrate across the liver sinusoidal endothelium to successfully engraft and restore liver function. Lastly, we concisely summarize the evolving field of porous membranes for the study of TEM.

Highlights

  • The vascular system exists as a connection between all tissues and organs

  • While the mechanisms and reasons for cell dissemination and extravasation may differ in these scenarios, one inevitable step in each case is the crossing of the vascular endothelial barrier, known as transendothelial migration (TEM)

  • A complementary in vitro study utilizing high-resolution immunofluorescence to observe PECAM-1 and endothelial cell (EC) membrane dynamics concluded what we believe to be the main function of PECAM-1 in TEM: PECAM-1 signaling mobilizes membrane from a cellular region known as the lateral border recycling compartment (LBRC) [67] to the site of leukocyte TEM, increasing EC membrane surface area and surrounding the immune cell in the intermediate stages of diapedesis [68]

Read more

Summary

Introduction

The vascular system exists as a connection between all tissues and organs. In addition to a plethora of soluble molecules, many cell types are critically circulated by blood flow throughout the body. For both a variety of inflammatory diseases and cancers, in vitro platforms that permit the study of leukocyte or cancer cell transmigration may help elucidate novel drug targets promoting beneficial, or limiting damaging, cell extravasation.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call